Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

Hirotugu Yamada1*†, Atsushi Tanaka2†, Kenya Kusunose1, Rie Amano1, Munehide Matsuhisa3, Hiroyuki Daida4, Masaaki Ito5, Hiroyuki Tsutsui6, Mamoru Nanasaki7, Haruo Kamiya8, Yasuko K. Bando9, Masato Odawara10, Hisako Yoshida11, Toyoaki Murohara9, Masataka Sata1, Koichi Node2* and for the PROLOGUE Study Investigators

Abstract

Background: Diabetes is associated closely with an increased risk of cardiovascular events, including diastolic dysfunction and heart failure that leads to a shortening of life expectancy. It is therefore extremely valuable to evaluate the impact of antidiabetic agents on cardiac function. However, the influence of dipeptidyl peptidase 4 inhibitors on cardiac function is controversial and a major matter of clinical concern. We therefore evaluated the effect of sitagliptin on echocardiographic parameters of diastolic function in patients with type 2 diabetes as a sub-analysis of the PROLOGUE study.

Methods: Patients in the PROLOGUE study were assigned randomly to either add-on sitagliptin treatment or conventional antidiabetic treatment. Of the 463 patients in the overall study, 115 patients (55 in the sitagliptin group and 60 in the conventional group) who had complete echocardiographic data of the ratio of peak early diastolic transmirtal flow velocity (E) to peak early diastolic mitral annular velocity (e') at baseline and after 12 and 24 months were included in this study. The primary endpoint of this post hoc sub-analysis was a comparison of the changes in the ratio of E to e' (E/e') between the two groups from baseline to 24 months.

Results: The baseline-adjusted change in E/e' during 24 months was significantly lower in the sitagliptin group than in the conventional group (−0.18 ± 0.55 vs. 1.91 ± 0.53, p = 0.008), irrespective of a higher E/e' value at baseline in the sitagliptin group. In analysis of covariance, sitagliptin treatment was significantly associated with change in E/e' over 24 months (β = −9.959, p = 0.001), independent of other clinical variables at baseline such as blood pressure, HbA1c, and medications for diabetes. Changes in other clinical variables including blood pressure and glycemic parameters, and echocardiographic parameters, such as cardiac structure and systolic function, were comparable between the two groups. There was also no significant difference in the serum levels of N-terminal-pro brain natriuretic peptide and high-sensitive C-reactive protein between the two groups during the study period.

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Conclusions: Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24 months attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e') independent of other clinical variables such as blood pressure and glycemic control.

Trial registration UMIN000004490 (University Hospital Medical Information Network Clinical Trials). https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005356; registered November 1, 2010

Keywords: Sitagliptin, T2DM, Echocardiography, Diastolic function, NT-proBNP

Background
Type 2 diabetes mellitus (T2DM) is associated closely with an increased risk of cardiovascular (CV) events including heart failure [1, 2]. The prevalence of patients who develop heart failure is greater in diabetic individuals than in non-diabetic individuals, and diabetes is known to be a strong risk factor for the development of heart failure [3]. It has been shown that once individuals with T2DM developed heart failure their 5-year survival rate was 12.5%, a rate considerably lower than in individuals without heart failure [3]. Furthermore, diabetes contributes to a worse outcome in patients with left ventricular (LV) diastolic dysfunction than those with systolic dysfunction [5]. However, intensive glucose-lowering therapy with antidiabetic agents does not always reduce the risk of heart failure [6], with some agents having unfavorable clinical effects on heart failure [7, 8]. Therefore, it is important to evaluate the impact of antidiabetic agents on cardiac function [9, 10].

To date, three randomized controlled trials that focused on major CV outcomes in patients with T2DM treated with either dipeptidyl peptidase-4 (DPP-4) inhibitors or placebo have been reported. Alogliptin in the EXAMIN [11], saxagliptin in the SAVOR-TIMI 53 [12], and sitagliptin in the TECOS [13] all showed non-inferior to placebo to lower the risk of the composite primary endpoint of CV death, myocardial infarction or ischemic stroke. However, in the SAVOR-TIMI 53 trial a 27% increase in the rate of hospital admission for heart failure was found in the group with saxagliptin [14]. Results from meta-analyses of randomized trials also demonstrated that DPP-4 inhibitors were associated with an increased risk of heart failure [15, 16]. In contrast, there was no significant difference in the rate of hospital admissions for heart failure between sitagliptin and placebo groups in the TECOS trial. Taken together, these results show the influence of DPP-4 inhibitors on cardiac function is still a major clinical concern.

The PROLOGUE study (University hospital medical Information Network Center: ID 000004490) was a prospective multicenter study conducted in Japan to evaluate the inhibitory effect of sitagliptin on the progression of atherosclerosis based on carotid-artery intima-media thickness (IMT) assessed by ultrasonography over a 2-year follow-up period [17, 18]. In this study, echocardiography at baseline and after 12 and 24 months of treatment was an optional examination. In order to elucidate the effect of DPP-4 inhibitor on cardiac function we carried out a sub-study of the PROLOGUE study that investigated the effect of sitagliptin on two-dimensional and Doppler echocardiographic parameters, mainly focusing on left ventricular diastolic function from baseline to 24 months.

Methods
Study design
The details of the PROLOGUE study design have been published elsewhere [17]. Briefly, the study was a multicenter, randomized, prospective, open-label, blinded-endpoint trial carried out at 48 institutions in Japan. A total of 463 patients older than 30 years who had T2DM with an HbA1c level of 6.2–9.4% despite conventional treatment with diet, exercise, and/or pharmacologic therapy with oral antidiabetic agents (except incretin-related therapy) for more than 3 months were enrolled in the study between June 2011 and September 2012. Patients with severe heart failure with a New York Heart Association (NYHA) functional classification of III and IV were excluded. The inclusion and exclusion criteria for the study have been published previously [17, 18]. The patients were assigned randomly using a 1:1 ratio to either add-on sitagliptin treatment (sitagliptin group, n = 232) or conventional glucose-lowering treatment (conventional group, n = 231). The primary endpoint of the PROLOGUE study was the change in mean common carotid IMT 24 months after treatment randomization. Echocardiography was performed as an ad hoc examination at baseline and 12 and 24 months after treatment randomization. The ethical committees of each participating institution approved the study protocol, with written informed consent for participation in the study being obtained from all the subjects.

Study population
Of the 436 participants in the PROLOGUE study, an echocardiographic examination was performed at baseline in 152 patients in the sitagliptin group and 148 patients in the conventional group. The present study
analyzed the data of 115 patients (55 patients in the sitagliptin group and 60 patients in the conventional group) who had echocardiographic data of the ratio of peak early diastolic transmitral flow (TMF) velocity (E) to peak early diastolic mitral annular velocity (e’) at baseline and at both 12 and 24 months (Fig. 1).

**Echocardiographic examination**

Echocardiography was performed in a standard manner using commercially available ultrasound diagnostic machines with various hemodynamic parameters being measured at each institution. The recordings and measurements were performed in accordance with the guidelines issued by the American Society of Echocardiography [19]. TMF velocity was recorded from the apical long-axis or four-chamber view. The ratio of the peak early diastolic (E) and the peak atrial systolic (A) TMF velocities was calculated. The deceleration time (DT) of early TMF velocity was also measured. The mitral annular motion velocity pattern was recorded from the apical four-chamber view with the sample volume located at the lateral or septal side of the mitral annulus using pulsed tissue Doppler echocardiography. The mean peak early diastolic mitral annular velocity (e’) in the septal and lateral side was measured, and the ratio of E to e’ (E/e’) then calculated as a marker of LV filling pressure. In addition to these diastolic parameters, routine echocardiographic parameters were also measured and included

---

**Fig. 1** Study participant flow diagram. E/e’: ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e’).
LV end-diastolic dimensions (LVDd) and LV end-systolic dimensions (LVDs) measured from M-mode or 2-dimensional echocardiogram of the LV. Fractional shortening was calculated as (LVDs—LVDs)/LVDdx100. The LV ejection fraction (LVEF) was measured and calculated from the apical two- and four-chamber view using a modified Simpson's method. LV mass was calculated as reported previously [20]. Relative wall thickness was calculated as two times posterior wall thickness divided by LVDd [21]. All Doppler recordings were performed during an end-expiratory breath hold. The mean values of three consecutive cardiac cycles were used in the analysis. Measurement and interpretation of the echocardiography was performed locally at each institution. The readers were blinded to the patients' assignment to treatment.

Laboratory examination
Blood samples were collected at baseline and after 12 and 24 months. The parameters analyzed are listed in Table 1. The serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitive CRP were measured in a centralized laboratory (SRL Co. Tokyo, Japan) using an electrochemiluminescence immunoassay (ECLIA) and nephelometry, respectively.

Statistical analysis
Data were expressed as mean ± standard deviation for normally distributed variables, median and interquartile range for variables with a skewed distribution, and frequencies (%) for categorial variables. All reported probability values were two-sided with a p value <0.05 considered statistically significant. The percentage changes in the variables during the study period were calculated as (values obtained at 12 or 24 months after treatment randomization—the baseline value)/baseline value. The differences between the two groups were assessed, where appropriate, by either the Student's t test, Mann–Whitney test, or Fisher's exact test. Variables with a skewed distribution were analyzed in the analysis of covariance after logarithmic conversion. We performed baseline-adjusted and multivariable regression analysis to confirm differences between the two groups. All the analyses were conducted using the JMP software program, version 12.1.0 (SAS Institute Inc., Cary, NC, USA).

Results
Clinical characteristics
Table 1 shows a comparison of the clinical characteristics at baseline and at 24 months and baseline-adjusted changes after 24 months of glycemic control between the two patient groups. There was no difference in body mass index and blood pressure between the groups throughout the study, while heart rate was increased in the sitagliptin group at 24 months. Although more than 70% of the subjects had hypertension, blood pressure was well controlled in both groups. Other parameters, such as lipid and renal profiles, were similar in the two groups throughout the study. The incidence of a previous history of CV diseases, including heart failure was not different in the two groups. Although the use of background medications for hypertension, dyslipidemia, or diabetes at baseline was also comparable in the groups, the incidence of some types of antidiabetic agent increased during the treatment period. This was especially apparent in the conventional group, possibly due to many patients achieving the glycemic control goal (HbA1c <6.2%) set in the PROLOGUE study protocol.

Glycemic control and neurohumoral effects
The levels of fasting plasma glucose, HbA1c, and 1, 5 AG were similar at baseline in the two groups and there were no significant changes in these parameters during the 24 months of treatment between the groups (Table 1). These results indicate similar degrees of improved glycemic control had been achieved. The serum levels of NT-proBNP and high-sensitive CRP were also similar at baseline and after 24 months of treatment.

Echocardiographic parameters
A comparison of echocardiographic parameters at baseline and after 24 months of treatment and baseline-adjusted changes after 24 months of treatment in both groups is shown in Table 2. Although baseline E/e′ was significantly higher in the sitagliptin group than in the conventional group, the baseline-adjusted change in E/e′ during 24 months of treatment was significantly lower in the sitagliptin group than in the conventional group (Fig. 2a). Analysis of covariance showed this difference remained significant (sitagliptin group, −30.9 ± 9.8%/24 months; conventional group, −11.0 ± 9.0%/24 months; p = 0.001, Table 3), even after adjustment for various confounding factors, such as age, sex, baseline systolic blood pressure, baseline HbA1c, history of CV diseases, history of heart failure, baseline medications for diabetes, baseline E/A, baseline LVEF, and baseline LV mass index. Other parameters relevant to diastolic function such as e′, E/A, and DT were similar in the two groups during the 24 months of treatment (Table 2; Fig. 2b). There were also no significant differences in parameters of cardiac structure and systolic function at baseline and 24 months, or baseline-adjusted changes after 24 months of treatment between the two groups (Table 2; Fig. 2c, d).
Table 1 Clinical characteristics between the two groups

| Variables                          | Baseline                    | 24 months                  | Least square means of baseline-adjusted changes |
|------------------------------------|-----------------------------|----------------------------|-----------------------------------------------|
|                                    | Sitagliptin (n = 55)        | Conventional (n = 60)      | Sitagliptin (n = 55)                          | Conventional (n = 60) |
|                                    | p value                     | p value                    | p value                                       | p value              |
| Age, year                          | 69 ± 8                      | 69 ± 9                     | 0.097                                         |                             |
| Gender (male/female)               | 38/17                       | 39/21                      | 0.064                                         |                             |
| Body mass index, kg/m²             | 25.9 ± 3.3                  | 24.8 ± 3.9                 | 0.098                                         | −0.10 ± 0.16            |
| Systolic BP, mmHg                  | 132 ± 17                    | 129 ± 19                   | 0.287                                         | 1.70 ± 2.20            |
| Diastolic BP, mmHg                 | 74 ± 11                     | 71 ± 12                    | 0.090                                         | 1.76 ± 1.47            |
| Heart rate, beats/min              | 70 ± 12                     | 67 ± 12                    | 0.196                                         | 3.37 ± 1.49            |
| Total cholesterol, mmol/L          | 4.4 ± 0.8                   | 46 ± 0.9                   | 0.43                                          | −0.08 ± 0.09            |
| HDL cholesterol, mmol/L            | 1.3 ± 0.3 (n = 55)          | 1.4 ± 0.4 (n = 58)         | 0.617                                         | −0.03 ± 0.03            |
| Triglycerides, mmol/L              | 3.1 [2.2–4.5] (n = 54)      | 3.1 [2.3–4.2] (n = 54)     | 0.536                                         | 0.06 ± 0.06             |
| Creatinine, µmol/L                 | 71.6 [61.9–86.6]            | 68.1 [59.2–89.3]           | 0.496                                         | 2.65 ± 1.77             |
| eGFR, mL/min/1.73 m²               | 666 ± 159                   | 673 ± 18.4                 | 0.834                                         | −1.96 ± 1.10            |
| Fasting plasma glucose, mmol/L     | 7.5 ± 1.8 (n = 53)          | 7.1 ± 14                   | 0.135                                         | −0.41 ± 0.20            |
| HbA1c, %                           | 7.0 ± 0.6                   | 69 ± 0.5                   | 0.737                                         | −0.47 ± 0.08            |
| 1,5AG, µg/mL                       | 139 [83–203.3]              | 156 [10.7–22.8]            | 0.086                                         | 2.55 ± 0.82             |
| NT-proBNP, pg/mL                   | 111.5 [42.1–240.8]          | 996 [52.1–234.9]           | 0.848                                         | 0.09 ± 0.08             |
| High-sensitive CRP, ng/mL          | 540 [279–1100]              | 576 [236–1618]             | 0.952                                         | −0.06 ± 0.16            |
| Current smoker, n (%)              | 8 (17.4) (n = 48)           | 13 (28.3) (n = 46)         | 0.321                                         | 0.06 ± 0.15             |
| Hypertension, n (%)                | 45 (81.8)                   | 46 (76.7)                  | 0.497                                         |                             |
| Dyslipidemia, n (%)                | 42 (76.4)                   | 42 (70.0)                  | 0.530                                         |                             |
| Cardiovascular disease, n (%)      | 8 (14.6)                    | 4 (6.7)                    | 0.226                                         |                             |
| Chronic heart failure, n (%)       | 38 (69.1)                   | 41 (68.3)                  | 0.930                                         |                             |
| Medications                        | 3 (5.5)                     | 7 (11.7)                   | 0.326                                         |                             |
| ACE inhibitor or ARB               | 37 (67.3)                   | 42 (70.0)                  | 0.753                                         | 39 (70.9)               |
| β-blocker                          | 12 (21.8)                   | 11 (18.3)                  | 0.641                                         | 39 (65.0)               |
| Diuretic                           | 17 (30.9)                   | 12 (20.0)                  | 0.178                                         | 15 (25.0)               |
| Statin                             | 42 (76.4)                   | 40 (66.7)                  | 0.251                                         | 39 (65.0)               |

Yamada et al. Cardiovasc Diabetol (2017) 16:63
Data for categorical variables are given as number (%); data for continuous variables given as mean ± standard deviation or median [interquartile range]. Skewed data was calculated after logarithmic translation. In the right column, values are shown as baseline-adjusted least square mean ± standard error.

**BP** blood pressure, **HDL** high-density lipoprotein, **eGFR** estimated glomerular filtration rate, **1,5AG** 1,5-anhydroglucitol, **1,4AG** 1,4-anhydro-glucitol, **NT-proBNP** N-terminal pro-brain natriuretic peptide, **CRP** C-reactive protein. **ACE** angiotensin-converting enzyme, **ARB** angiotensin receptor blocker.

| Variables                      | Baseline |                    | Least square means of baseline-adjusted changes |
|--------------------------------|----------|--------------------|-----------------------------------------------|
|                                | Sitagliptin (n = 55) | Conventional (n = 60) | p value | Sitagliptin (n = 55) | Conventional (n = 60) | p value |
| α-Glucosidase inhibitor, n (%) | 23 (41.8) | 30 (50.0)          | 0.455  | 18 (32.7)          | 38 (63.3)          | 0.001   |
| Glinide, n (%)                 | 4 (7.3)   | 4 (6.7)            | 0.899  | 2 (3.6)            | 5 (8.3)            | 0.293   |
| Biguanide, n (%)               | 9 (16.4)  | 10 (16.7)          | 0.965  | 12 (21.8)          | 16 (26.7)          | 0.545   |
| Sulfonylurea, n (%)            | 9 (16.4)  | 12 (20.0)          | 0.638  | 4 (7.3)            | 18 (30.0)          | 0.002   |
| Thiazolidinedione, n (%)       | 11 (20.0) | 18 (30.0)          | 0.283  | 9 (16.4)           | 23 (38.3)          | 0.009   |
Table 2  Comparisons of echocardiographic parameters at baseline, 24 months and baseline-adjusted changes after 24 months of glycemic control

| Variables                          | Baseline                     | 24 months                  | Least square means of baseline-adjusted changes |
|------------------------------------|------------------------------|----------------------------|-----------------------------------------------|
|                                    | Sitaglptin (n = 55)          | Conventional (n = 60)      | Sitaglptin (n = 55)                          | Conventional (n = 60)      | Sitaglptin (n = 55)                          | Conventional (n = 60)     | p value |
| TMF-E, cm/s                        | 74.2 ± 32.6                  | 69.3 ± 31.0                | 73.1 ± 33.4                                 | 73.6 ± 34.3                | −0.85 ± 2.37                                 | 404 ± 2.27                  | 0.139 |
| e′, cm/s                           | 6.35 ± 1.72                  | 7.03 ± 2.13                | 660 ± 2.19                                 | 6.76 ± 2.11                | 0.13 ± 0.23                                 | −0.16 ± 0.22                 | 0.370 |
| E/e′                               | 12.17 ± 5.20                 | 10.34 ± 4.18               | 12.19 ± 6.93                               | 12.06 ± 7.06               | −0.18 ± 0.55                               | 1.91 ± 0.53                  | 0.008 |
| TMF-A, cm/s                        | 80.1 ± 203 (n = 48)          | 83.4 ± 21.3 (n = 54)       | 82.4 ± 19.3 (n = 48)                        | 88.2 ± 22.9 (n = 55)       | 3.06 ± 2.10 (n = 47)                        | 5.73 ± 1.96 (n = 54)        | 0.354 |
| E/A                                | 0.91 ± 0.52 (n = 48)         | 0.79 ± 0.24 (n = 54)       | 0.86 ± 0.35 (n = 48)                        | 0.81 ± 0.31 (n = 54)       | −0.03 ± 0.04 (n = 48)                       | −0.04 ± 0.04 (n = 54)       | 0.825 |
| Deceleration time, msec            | 233.5 ± 65.8 (n = 50)        | 237.6 ± 67.7 (n = 55)      | 238.1 ± 78.1 (n = 52)                       | 240.6 ± 64.6 (n = 58)      | 9.3 ± 906 (n = 49)                          | 5.38 ± 8.63 (n = 54)        | 0.741 |
| LV end-diastolic dimension, mm     | 48.5 ± 5.6                   | 48.6 ± 5.9                 | 47.5 ± 5.7                                 | 47.7 ± 5.3                 | −1.04 ± 0.51                               | −0.91 ± 0.48                  | 0.855 |
| LV end-systolic dimension, mm      | 31.7 ± 6.1                   | 32.6 ± 7.2                 | 31.5 ± 7.1                                 | 31.6 ± 6.9                 | −0.3 ± 0.60                                | −0.94 ± 0.58                  | 0.447 |
| Fractional shortening, %           | 35.1 ± 6.7                   | 33.6 ± 7.9                 | 33.9 ± 13.3                                | 34.4 ± 8.5                 | −1.05 ± 1.31                               | 0.64 ± 1.25                  | 0.355 |
| LV ejection fraction, %            | 63.6 ± 9.6                   | 60.8 ± 10.8                | 62.5 ± 9.3                                 | 61.9 ± 9.8                 | −0.63 ± 0.85                               | 0.67 ± 0.81                   | 0.273 |
| LV mass, g                         | 130.0 ± 666                  | 160.2 ± 56.3               | 159.9 ± 49.1                               | 159.2 ± 52.9               | −10.29 ± 4.94                              | −3.50 ± 4.73                  | 0.324 |
| LV mass index, g/m²                | 101.6 ± 35.0                 | 96.2 ± 30.6                | 94.8 ± 26.3                                | 95.6 ± 28.3                | −5.50 ± 2.81                               | −1.80 ± 2.68                  | 0.343 |
| Relative wall thickness            | 0.40 ± 0.09                  | 0.38 ± 0.08                | 0.41 ± 0.08                                | 0.39 ± 0.08                | 0.01 ± 0.01                                | 0.00 ± 0.01                   | 0.886 |
| LA dimension, mm                   | 408.6 ± 69 (n = 54)          | 400.7 ± 76 (n = 58)        | 397.6 ± 69 (n = 50)                        | 403.6 ± 69 (n = 50)        | −0.87 ± 0.55                               | 0.25 ± 0.54 (n = 58)         | 0.151 |

Data for categorical variables are given as number (%); data for continuous variables given as mean ± standard deviation. In the right column, values are shown as baseline-adjusted least square mean ± standard error. TMF = transmitial flow velocity, E = early diastolic velocity, e′ = early diastolic mitral annular velocity. LV = left ventricular, LA = left atrial.
Fig. 2  Percentage changes in E/e', e', LVEF, and LVMI at 12 and 24 months in the two treatment groups. Each graph shows sex-, age- and baseline-adjusted least square means (± standard error) at 12 and 24 months. The %change values were calculated as (24 or 12 month data-baseline)/baseline. E/e' at 24 months shows significant difference between the two groups. E peak early diastolic transmitral flow velocity, e' peak early diastolic mitral annular velocity, LVEF left ventricular ejection fraction, LVMI left ventricular mass index. *p = 0.002 vs. sitagliptin group

Table 3  Factors associated with change in E/e' from baseline to 24 months

|                     | Model 1                                      | Model 2                                      | Model 3                                      |
|---------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                     | N = 115, R = 0.26                            | N = 115, R = 0.27                            | N = 115, R = 0.55                            |
|                     | β p value                                    | β p value                                    | β p value                                    |
| Sitagliptin         | −8.910 0.006                                 | −8.887 0.007                                 | −9.959 0.001                                 |
| E/e'                | −0.094 0.889                                 | −0.159 0.820                                 | −0.240 0.716                                 |
| Male gender         | 0.674 0.845                                  | 0.149 0.966                                  | −0.005 0.990                                 |
| Age                 | 0.330 0.392                                  | −0.005 0.990                                 | −0.005 0.990                                 |
| Systolic blood pressure | 6.614 0.272                                  | −5.631 0.142                                 | 10.819 0.070                                 |
| HbA1c               | −0.293 0.095                                 | −5.631 0.142                                 | 10.819 0.070                                 |
| Cardiovascular disease | 10.819 0.070                                | 10.819 0.070                                 | 10.819 0.070                                 |
| Chronic heart failure | 1.053 0.734                                 | 1.053 0.734                                 | 1.053 0.734                                 |
| α-glucosidase inhibitor | −14.839 0.001                              | −14.839 0.001                               | −14.839 0.001                               |
| Biguanide           | −10.778 0.072                                | −10.778 0.072                                | −10.778 0.072                                |
| Glinide             | 2.159 0.572                                  | 2.159 0.572                                  | 2.159 0.572                                  |
| Sulfonylurea        | −0.567 0.891                                 | −0.567 0.891                                 | −0.567 0.891                                 |
| Thiazolidinedione   | 0.178 0.602                                  | 0.178 0.602                                  | 0.178 0.602                                  |
| LV ejection fraction | 0.348 <0.001                                 | 0.348 <0.001                                 | 0.348 <0.001                                 |

Model 1 means ANCOVA adjusted for baseline E/e'. Model 2 were adjusted for Model 1 and sex, age. Model 3 were adjusted for Model 2 and systolic blood pressure, HbA1c, cardiovascular disease, chronic heart failure, α-glucosidase inhibitor, biguanide, glinide, sulfonylurea, thiazolidinedione, LV ejection fraction, LV mass index, whose data were obtained at baseline examination.

Abbreviations, see Tables 1 and 2.
Discussion
The present study was a subgroup analysis of the PROLOGUE trial that focused on the effect of sitagliptin on echocardiographic parameters of diastolic function. The key finding of the study was that addition of sitagliptin to conventional diabetic care significantly attenuated the increase in echocardiographic parameters of diastolic function (E/e'), relative to conventional treatment alone. On the other hand, changes in other parameters such as LV size and LVEF did not differ between the two groups. We also found no significant differences in the biomarkers measured during the study. It is known that metabolic disturbances and diabetes are associated closely with cardiac diastolic dysfunction such as diabetic cardiomyopathy, and there is also evidence that patients with diabetes and an increased E/e' have higher mortality [22, 23].

Given these results, it appears that sitagliptin treatment may have a protective effect on cardiac diastolic function, leading to improved prognosis independent of glycemic control and blood pressure.

Recently we demonstrated a possible effect of sitagliptin on carotid atherosclerosis [18], endothelial function [24], and arterial stiffness [25] using data of the PROLOGUE study. This series of studies did not show beneficial effects of sitagliptin treatment on these variables, relative to conventional glucose-lowering treatment with the exception of incretin-related agents, with better glycemic control being observed in the sitagliptin treatment group. In contrast, there is another report that additional administration of DPP-4 inhibitors, including sitagliptin, to conventional antidiabetic regimes significantly attenuated the progression of carotid IMT [26, 27]. Although the participants' backgrounds including age, concomitant agents, and severity of diabetes differed between these studies [18], these findings suggest that DPP-4 inhibitors at least cause no harm to the vasculature and are useful for glycemic control in the usual clinical settings. The findings are also consistent with the results of a large CV outcome trial [13]. This led us to investigate the effect of sitagliptin on cardiac function and biomarkers in the current sub-group analysis of the PROLOGUE study data.

DPP-4 inhibitors promote glucose-dependent insulin secretion and suppress glucagon secretion by inhibiting the activity of an enzyme which inactivates endogenous incretin like glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide. This leads to improved postprandial hyperglycemia similar to that seen with the normal physiological response. DPP-4 inhibitors do not cause weight gain and a single administration is unlikely to induce hypoglycemia. It is therefore relatively easy to use DPP-4 inhibitors safely in the elderly and patients with renal dysfunction. To date, the three randomized clinical trials mentioned above have reported non-inferiority, relative to placebo, for CV outcomes in patients with T2DM with high cardiovascular risk or established CV disease [11–13]. In particular, the rate of hospitalization for heart failure was similar between sitagliptin and placebo treatments in the TECOS trial [13], despite the SAVOR-TIMI 53 trial showing that saxagliptin, another DPP-4 inhibitor, significantly increased the hospitalization rate [12]. However, because these trials did not fully investigate CV physiological functions and relevant biomarkers, it proved difficult to determine how DPP-4 inhibitors affected cardiac function. Mechanistic studies using these surrogate markers are therefore required to determine the possible actions of DPP-4 inhibitors on the CV system.

Accumulated evidence suggests that patients with T2DM often exhibit LV diastolic dysfunction and heart failure due to underlying metabolic derangement, such as insulin resistance, independent of hypertension and coronary artery disease (CAD) [28–30]. Recent studies have also demonstrated that DPP-4 activity correlates with cardiac systolic and diastolic dysfunction and remodeling via several molecular pathways, such as increased inflammation and altered angiogenesis [31–34]. Experimental studies have shown that sitagliptin improved survival rate and cardiac function in an ischemia–reperfusion mice model [35] and reduced infarction size in a myocardial infarction mice model [36]. Long-term administration of sitagliptin was also shown to suppress the onset of heart failure in a rat model of heart failure [31]. A meta-analysis of clinical trials also described the advantages of DPP-4 inhibitors on risk reduction in CV events and death compared with other antidiabetic agents [37].

Sitagliptin treatment in T2DM patients with CAD also improved parameters of diastolic function and cardiac dysfunction due to post-ischemic stunning during dobutamine stress echocardiography [38]. In contrast, sitagliptin treatment did not improve systolic function in T2DM patients with ischemic heart failure [39]. Furthermore, Oe et al. [40] reported that sitagliptin treatment in T2DM patients with LV diastolic dysfunction was not associated with improvement in the relevant echocardiographic parameters. As a consequence of these different findings the therapeutic effect of DPP-4 inhibitors on cardiac function remains controversial.

In the present study, adding sitagliptin to usual diabetes treatment significantly attenuated the annual increase in E/e', suggesting a preventive effect on LV compliance and diastolic dysfunction. However, sitagliptin treatment did not affect other echocardiographic parameters of systolic function and cardiac structures or other clinical variables, such as NT-proBNP, blood pressure, and
glycemic control. Comparison with a previous study in which sitagliptin did not improve diastolic dysfunction [40] showed the following differences: (1) all participants in the previous study were diagnosed with diastolic dysfunction at baseline; (2) the treatment period was 6 months vs. 24 months in the PROLOGUE study; (3) the comparator was voglibose vs. any antidiabetic agents except for incretin-related in the PROLOGUE study. While these differences may have affected the results of the studies, the precise mechanisms by which sitagliptin suppressed the increase in diastolic parameter values were not confirmed in our study. As reported previously [40], the increased incidence of concomitant use of thiazolidinediones in the conventional group may have enhanced the acceleration of E/e′ values. Nogueira et al. also reported that beneficial effects in LV diastolic function were observed in T2DM patients on insulin treated with sitagliptin, while the effects were not as apparent in T2DM patients treated with insulin only [41]. That study also reported a possible association between the sitagliptin-mediated improvement in diastolic dysfunction and increase in plasma GLP-1 levels. However, we did not measure this incretin in the current study. It is thought that GLP-1 has a wide spectrum of CV protective effects [42]. In fact, treatment with a GLP-1 agonist, one of the incretin-related agents, was shown to improve diastolic function beyond and independent of glycemic control [43]. Because there remains clinical caution regarding DPP-4 inhibitor-induced heart failure [44, 45], further experimental and clinical research is required to elucidate the precise mechanisms by which DPP-4 inhibitors affect diastolic function and heart failure in patients with T2DM.

Limitations
The present study was a sub-analysis of the PROLOGUE study. Because echocardiography was a voluntary measurement in the PROLOGUE study and not performed in all participants, the number of patients in this study was small and included only Japanese subjects. Whether or not echocardiography was performed was left to the judgment of each researcher and therefore selection bias could not be fully excluded. The sample size may therefore be underpowered and accordingly the clinical implications may be limited. In addition, the PROLOGUE study recruited patients with and without history of heart failure at baseline, with patients with a NYHA functional classification of III and IV being excluded. Because most patients had no history of heart failure evident at baseline, we did not determine whether there were differences in the effects of sitagliptin on diastolic function between patients with or without heart failure. Further studies on a larger number of subjects are needed to assess whether longer-term DPP-4 inhibitor treatment is safe and has beneficial effect on cardiac function in T2DM patients with or without overt heart failure.

Conclusions
Our present sub-group analysis from the PROLOGUE study demonstrated that adding sitagliptin to conventional anti-diabetic regimens for 24 months in patients with T2DM attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction, E/e′, independent of other clinical variables such as blood pressure and glycemic control. These results suggest that sitagliptin is potentially a beneficial agent for diastolic function in patients with T2DM.

Additional file

Additional file 1. The PROLOGUE Study Investigators.

Abbreviations
A: peak atrial systolic transmitral flow velocity; CAD: coronary artery disease; CV: cardiovascular; DPP-4: dipeptidyl peptidase-4; DT: deceleration time; E: peak early diastolic transmitral flow velocity; e′: peak-early diastolic mitral annular velocity; EF: ejection fraction; GLP-1: glucagon-like peptide-1; IMT: intima-media thickness; LV: left ventricular; LVEDD: left ventricular end-diastolic dimensions; LVEDs: left ventricular end-systolic dimensions; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA: New York Heart Association; TMF: transmitral flow; T2DM: type 2 diabetes mellitus.

Authors’ contributions
HY and AT wrote the draft of the article, which was critically supervised by MS and KN. HY performed statistical analysis throughout this study. KK, RA and MM confirmed data collection and study selection criteria. HD, MI, HT, MN, HK, YKB, MO, and TM enrolled patients and performed study quality assessment. All authors approved the final version of manuscript.

Author details
1 Department of Cardiovascular Medicine, Tokushima University Hospital, 2-50-1 Kuramoto, Tokushima, Japan. 2 Department of Cardiovascular Medicine, Saga University, 5-5-1 Nabeshima, Saga, Japan. 3 Department of Diabetes Therapeutics and Research Center, Tokushima University, Tokushima, Japan. 4 Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. 5 Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan. 6 Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. 7 Cardiovascular Center, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan. 8 Division of Cardiology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan. 9 Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 10 Department of Diabetes, Endocrinology, Metabolism and Rheumatology, Tokyo Medical University, Tokyo, Japan. 11 Clinical Research Center, Saga University, Saga, Japan.

Acknowledgements
The authors thank the participants and staff for their essential contributions to the PROLOGUE study. The PROLOGUE study is a multicenter collaboration. In addition to the listed authors, the PROLOGUE Study Investigators listed in Additional file 1 were involved in this study.
Competing interests
HFa received honoraria from MSD, research grant from MSD and Ono. AT, KK, and RA declares no competing interests. MM received honoraria from Astellas, Eli Lilly, Mitsubishi Tanabe, Novo Nordisk, Sanofi, and Takeda. research grant from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmitKline, Kowa, Medtronic Japan, Mitsubishi Tanabe, Mochida, MSD, Ono, Pfizer, Sanofi, Shionogi, Takeda and Terumo, research funding from Abbott Vascular Japan, Astellas, Bayer, Boehringer Ingelheim, Boston Scientific Japan, Bristol-Myers, Daiichi Sankyo, Kaken, Kowa, MSD, Novartis, Otsuka, Pfizer, Philips Respironics GK, Sanofi, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon and Takeda. HF received honoraria from Daiichi Sankyo and Pfizer, research funding from Astellas, Biotronik, Bristol-Myers, Daiichi Sankyo, GlaxoSmithKline, Mitsubishi Tanabe, MSD, Novartis, Otsuka, Pfizer, Shionogi, Sumitomo Dainippon and Takeda. HT received honoraria from Bristol-Myers, Daiichi Sankyo, Mitsubishi Tanabe and Ono, research funding from Astellas, Boehringer Ingelheim, Boston Scientific Japan, Daiichi Sankyo, Mitsubishi Tanabe, Otsuka, Takeda and Teijin Pharma. MN declares no competing interests. HK declares no competing interests. YKB received honoraria from AstraZeneca, Mitsubishi Tanabe, MSD, and Takeda, research grant from AstraZeneca, Daiichi Sankyo, Mitsubishi Tanabe, MSD, and Takeda. MO received honoraria from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Kowa, Merck, Mitsubishi Tanabe, Novartis, Ono and Sanofi. HFa declares no competing interests. TM received honoraria from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Mitsubishi Tanabe, MSD, Pfizer, Sumitomo Dainippon and Takeda, research grant from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Mitsubishi Tanabe, MSD, Novartis, Otsuka, Pfizer, Sanofi, Sumitomo Dainippon, Takeda, and Teijin Pharma. KN received honoraria from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Merck, Mitsubishi Tanabe, Sanofi, and Takeda. MS received honoraria from MSD, research grant from MSD and Ono. KN received research funding from Astellas, Boehringer Ingelheim, Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan, Mitsubishi Tanabe, Sanwa Kagaku Kenkyusho, Takeda, and Teijin Pharma.

Availability of data and materials
The datasets analyzed during the current study are available from the corresponding authors on reasonable request (yamadah@tokushima-u.ac.jp, node@cc.saga-u.ac.jp).

Consent for publication
All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language. If the manuscript is accepted, we approve it for publication in Cardiovascular Diabetology.

Ethics approval and consent to participate
The ethical committees of the participating institutions approved the study design. Consent for publication is obtained from all subjects.

Funding
This study is supported by a research grant from the Clinical Research Promotion Foundation (No. 1026). The funding body had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 30 January 2017 Accepted: 4 May 2017
Published online: 11 May 2017

References
1. Kannell WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.
2. Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Cobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E et al. diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.
3. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. Lancet. 2015;385(9982):2107–17.
4. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevention, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699–703.
5. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377–85.
6. Turnbull FM, Abaraia C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–98.
7. Varas-Lorenzo C, Marquils AV, Pladervall M, Riera-Guardia N, Calingaert B, Hassell L, Romo S, Perez-Gutthann S. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014;14:129.
8. Komajda M, McCrae KA, Beck-Nielsen H, Gomis R, Hannefeld M, Pocock SJ, Curtis JS, Jones NP. Home PC. Heart failure events with ousightzone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824–31.
9. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2(10):843–51.
10. Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19(1):43–53.
11. White WB, Cannon CP, Heller SR, Nissen SE, Bergeman RW, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.
12. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
13. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Moglin J, Korn S, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):322–42.
14. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.
15. Siwertzen J, Rossmann J, Holst JJ, Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9(4):209–22.
16. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147–58.
17. Oyama J, Ishizu T, Sato Y, Kodama K, Bando YK, Murohara T, Node K. Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study. Int J Cardiol. 2014;174(2):383–4.
18. Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, Kamiya H, Ajoka M, Ishihara M, Dai K, et al. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial. PLoS Med. 2016;13(3):e1002051.
19. Lang RM, Biering M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanevise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2005;18(12):1440–63.
20. Devereux RB, Alonso DR, Lutas EM, Gottdieb GJ, Campo E, Sachs I, Rechek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8.

21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanevise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2005;18(12):1440–63.

22. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718–1727, 1727a–1727c.

23. From AM, Scott CG, Chen HH. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol. 2009;103(10):1463–6.

24. Maruhashi T, Higashi T, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Daki K, Ohno J, et al. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOUGE study. Cardiovasc Diabetol. 2016;15(1):134.

25. Tomiyama H, Miwa T, Kan K, Matsuhashi M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, et al. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOUGE study. Cardiovasc Diabetol. 2016;15(1):150.

26. Mita T, Katakami N, Shigeta T, Yoshii H, Onuma T, Kuriyabashi N, Onosoi T, Kaneto H, Kosugi K, Umahayara Y, et al. Sitagliptin attenuates the progression of cardiac intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39(3):455–64.

27. Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osono T, Shigeta T, Kosugi K, Umahayara Y, Yamamoto T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of cardiac atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPREAD-A). Diabetes Care. 2016;39(1):139–48.

28. Fontes-Caravello R, Ladeiras-Lopes R, Bettencourt P, Leite-Moreira A, Azevedo A. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol. 2015;144.

29. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660–71.

30. Fuentes-Antras J, Thiesis HQ, Vallaster M, Mehl U, Brunner S, David R, Fischer R, Krieg L, Hirsh C, Huber R, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell. 2009;4(4):313–23.

31. Sahuve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Hunsen MA, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetologia. 2010;53(4):1063–73.

32. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298(5):H1454–65.

33. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O’Keefe JH. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;109(8):826–33.

34. McCormick LM, Kyyd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging. 2014;7(2):274–81.

35. Arturi F, Succurro E, Micolli S, Cloro C, Rufio M, Maio R, Perticone M, Sesti G, Perticone F. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrin. 2016 Endocrin. 2016 Nov 9. [Epub ahead of print].

36. Oe H, Nakamura K, Kihara H, Shimpada K, Fukuoka S, Takagi T, Miyoshi T, Hirata K, Yoshikawa J, It0 H. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83.

37. Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL. Diabetic cardiomyopathy in type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor—a pilot study. Diabetes Metab Syndr. 2014;6(1):103.

38. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(1):1788–803.

39. Saponaro F, Sonaglioni A, Rossi A, Montefusco L, Lombardo M, Adda G, Arosio M. Improved diabetic function in type 2 diabetes after a six month liraglutide treatment. Diabetes Res Clin Pract. 2016;118:21–8.

40. Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ (Clin Res ed). 2016;352:i610.

41. Rehman MB, Tedrej BV, Soustrie J, Buisson M, Archambault P, Pouchain D, Vaillant-Roussel H, Gueffrier F, Faille JL, Perault-Pochat MC, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43(1):48–58.